Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

SIGA Technologies Announces $13 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)

Orders Received from Two New Jurisdictions, and a Country in the Asia Pacific Region under an Existing Contract

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced approximately $13 million of procurement orders for oral TPOXX (tecovirimat), including $11 million for initial procurement from two new international jurisdictions and an approximate $2 million order from a country in the Asia Pacific region that has an established contract for oral TPOXX (tecovirimat).

“Procurement orders from new international jurisdictions have occurred as SIGA Technologies has received a large and ongoing number of inquiries about accessing oral TPOXX, highlighting the importance of health security preparedness,” said Phil Gomez, CEO of SIGA. “We expect a portion of the courses of oral TPOXX delivered under these orders will be used for the treatment of active monkeypox cases and represent a first step in the response to this outbreak by the global public health community. By increasing both the scale and scope of TPOXX stockpiling, countries can be better prepared for the outbreak risks of smallpox, monkeypox, and other viruses in the orthopoxvirus family of viruses and make sure that patients are able to access a proven safe and effective treatment.”

The orders from the new international jurisdictions represent the first procurements of oral TPOXX (tecovirimat) directly in response to the evolving global monkeypox outbreak. One of the new jurisdictions is located in Europe and the other is located in the Asia Pacific region. SIGA currently expects to deliver approximately $4 million of oral TPOXX (tecovirimat) under the two new contracts within the next 45 days. The remaining approximately $7 million of oral TPOXX (tecovirimat) is expected to be delivered in 2023. With respect to the order from an existing customer, SIGA recently fulfilled the order by delivering $2 million of oral TPOXX (tecovirimat). In combination with a delivery of a previously disclosed order of $2.8 million, SIGA has delivered in total approximately $5 million of oral TPOXX (tecovirimat) to this country during this quarter.

Meridian Medical Technologies, LLC (Meridian) is the counterparty to the international contracts and SIGA will be responsible for the manufacture and delivery of product. “The recent cases of monkeypox are another reminder of how the emergence and re-emergence of infectious diseases continue to present global public health threats and underscore the critical importance of pandemic preparedness efforts,” said Tom Handel, Chief Commercial Officer at Meridian. “We are pleased to partner with SIGA to meet the demand for antiviral treatment, leveraging our company’s six decades of leadership in health security to ensure governments around the world are prepared to meet its health emergency needs and stockpiling requirements.”

On July 13, 2018, the US Food and Drug Administration (FDA) approved oral TPOXX for the treatment of smallpox to mitigate the impact of a potential outbreak or bioterror attack. In December 2021, oral TPOXX was approved for the same indication by Health Canada. Tecovirimat (TPOXX) was approved by the European Medicines Agency (EMA) in January 2022 with a broader label that covers the treatment of smallpox, monkeypox, cowpox, and complications from vaccination for smallpox.

ABOUT SIGA TECHNOLOGIES, INC. and TPOXX®

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a supply of TPOXX under Project BioShield. The oral formulation of TPOXX was approved by the FDA for the treatment of smallpox in 2018. The full label is available by clicking here. Oral tecovirimat received approval from the European Medicines Agency (EMA) in 2022. The EMA approval includes labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. The full label is available by clicking here. In September 2018, SIGA signed a contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, for additional procurement and development related to both oral and intravenous formulations of TPOXX. For more information about SIGA, please visit www.siga.com.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine